Aldeyra shares are down $3.32, or 31%, to $7.32 following the resumption of trading after the company announced receipt of a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration for the 505(b)(2) New Drug Application, or NDA, of ADX-2191, an investigational drug candidate for the treatment of primary vitreoretinal lymphoma, or PVRL.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALDX:
- Aldeyra Therapeutics Stock Plunges as FDA Rejects Drug
- Aldeyra announces receipt of Complete Response Letter for NDA of ADX-2191
- 3 Best Stocks to Buy Now, 6/16/2023, According to Top Analysts
- Aldeyra Soars on Promising Phase 3 Data in Allergic Conjunctivitis
- Aldeyra’s reproxalap study receives statistical significance for all endpoints
